...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of the advanced practitioner in oncology >Combination Therapies in Advanced, Hormone Receptor-Positive Breast Cancer
【24h】

Combination Therapies in Advanced, Hormone Receptor-Positive Breast Cancer

机译：先进，激素受体阳性乳腺癌的组合疗法

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

About 17% of women with breast cancer have locally advanced or metastatic disease at the time of diagnosis, and 30% to 40% of women diagnosed with early-stage disease will eventually have recurrence. The majority of breast cancers express estrogen or progesterone receptors, and hormonal therapies (HTs) remain the treatment of choice for these cancers after the resection of primary tumors. In addition to their effectiveness, HTs often have fewer severe side effects compared with chemotherapies. As breast cancer recurs or progresses, however, it becomes less responsive to successive HT, and the duration of response decreases. Recent advances have identified specific combinations of HTs that can extend the duration of response in appropriate patients with advanced breast cancer Furthermore, research into signaling pathways has led to the availability of targeted agents that improve efficacy and duration of response when used in combination with specific HTs. Despite their effectiveness and advantages, these combination therapies increase the burden of side effects and the care required for proper management. In addition, practitioners must educate patients about the increasing complexity regarding treatment decisions, and provide care as part of a patient-centered team that optimizes both the medical outcomes and quality of life of patients with breast cancer.
机译：在诊断时，约有17％的患有乳腺癌的女性患有局部晚期或转移性疾病，30％〜40％的患有早期疾病的女性最终会发生复发。大多数乳腺癌表达雌激素或孕酮受体，并荷尔蒙治疗（HTS）仍然是在切除原发性肿瘤后对这些癌症的选择。除了他们的有效性外，与化疗相比，HTS通常具有更少的严重副作用。然而，由于乳腺癌的衰退或进行，响应于连续的HT变得较小，并且响应的持续时间降低。最近的进展已经确定了HTS的特定组合，可以延长适当的乳腺癌患者中的响应持续时间，进一步的研究已经导致了当与特定HTS组合使用时改善响应效果和持续时间的可用性药物的可用性。尽管有其有效性和优势，但这些组合疗法增加了副作用的负担和适当管理所需的护理。此外，从业者必须教育患者关于治疗决策的增加复杂性，并作为患者中心团队的一部分提供护理，以优化乳腺癌患者的医疗结果和生活质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号